Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Issuances (2016 - 2021)

Sunshine Biopharma (SBFM) has disclosed Long-Term Debt Issuances for 7 consecutive years, with $1.4 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Long-Term Debt Issuances rose 168.39% year-over-year to $1.4 million, compared with a TTM value of $3.3 million through Dec 2021, up 98.21%, and an annual FY2021 reading of $3.3 million, up 98.21% over the prior year.
  • Long-Term Debt Issuances was $1.4 million for Q3 2021 at Sunshine Biopharma, up from $768500.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.4 million in Q3 2021 and bottomed at -$242502.0 in Q2 2019.
  • Average Long-Term Debt Issuances over 5 years is $394378.0, with a median of $249500.0 recorded in 2019.
  • The sharpest move saw Long-Term Debt Issuances crashed 104.25% in 2019, then skyrocketed 159135.37% in 2020.
  • Year by year, Long-Term Debt Issuances stood at $660565.0 in 2017, then dropped by 10.69% to $589920.0 in 2018, then decreased by 26.34% to $434560.0 in 2019, then skyrocketed by 129.57% to $997603.0 in 2020, then skyrocketed by 40.34% to $1.4 million in 2021.
  • Business Quant data shows Long-Term Debt Issuances for SBFM at $1.4 million in Q3 2021, $768500.0 in Q2 2021, and $1.2 million in Q1 2021.